ENGENE HOLDINGS INC (ENGN)
CA29286M1059 - Common Stock
enGene Reports Full Year 2024 Financial Results and Provides a Business Update
Engene Holdings Enters Oversold Territory (ENGN)
enGene to Participate in Upcoming Investor Conferences
enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
enGene Announces $60 Million Private Placement Financing
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Tuesday 10/1 Insider Buying Report: VRDN, ENGN
Engene Holdings Becomes Oversold (ENGN)
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort
enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update
enGene to Participate in Upcoming Investor Conferences
Engene Holdings Becomes Oversold (ENGN)
enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
enGene Announces Appointment of Ron Cooper as Chief Executive Officer
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
ENGN Stock Earnings: enGene Holdings Misses EPS for Q2 2024
ENGN stock results show that enGene Holdings missed analyst estimates for earnings per share the second quarter of 2024.
ENGN Stock Earnings: enGene Holdings Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips enGene Holdings (NASDAQ:ENGN) just reported results for the second quarter of 2...
enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update
Engene Holdings Breaks Below 200-Day Moving Average - Notable for ENGN
enGene to Present at the Jefferies Global Healthcare Conference
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
Relative Strength Alert For Engene Holdings
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting
/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN) or ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in...
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting
/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN) or ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program...
Engene Holdings is Now Oversold (ENGN)
enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development
/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead...
enGene Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development
/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead...
engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development
/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product...
/C O R R E C T I O N -- enGene Inc./
In the news release, engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development, issued 09-Apr-2024 by...
enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development
/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead...
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress
/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead...
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress
/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product...
enGene To Present at the Leerink Partners Global Biopharma Conference
/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN) or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in...